{"entity":{"id":"nct05442060","kind":"trial","name":"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic N","aka":[],"tldr":"A phase 2 trial of Erlotinib in non-small-cell lung cancer and small-cell lung cancer, run by OBI Pharma, Inc, now recruiting.","summary":"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05442060 by OBI Pharma, Inc, with 60 participants planned, started 2022-07-27 and due to reach its primary completion in 2025-12-31. Interventions recorded: 30 μg OBI-833/100 μg OBI-821, Erlotinib (150 mg daily). Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05442060","url":"https://clinicaltrials.gov/study/NCT05442060"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["erlotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05442060","phase":"2","setting":"A Randomized, Open-Label, Phase 2 Study to Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"OBI Pharma, Inc","enrolled":60,"outcomes":[]},"route":"/trials/nct05442060/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/"}]}}